Antibodies to the voltage-gated potassium channel (VGKC) complex and glutamic acid decarboxylase (GAD) have been reported in some cases of psychosis. We conducted the first systematic review and meta-analysis to investigate their prevalence in people with psychosis and report a case series of VGKCcomplex antibodies in refractory psychosis. Only five studies presenting prevalence rates of VGKC seropositivity in psychosis were identified, in addition to our case series, with an overall prevalence of 1.5% (25/1720) compared to 0.7% in healthy controls (12/1753). Meta-analysis established that the pooled prevalence of GAD65 autoantibodies was 5.8% (95% confidence interval [CI]: 2.0-15.6%; I 2 = 91%; nine studies) in psychotic disorders, with a prevalence of 4.6% (95%CI: 1.2-15.9%; nine studies; I 2 = 89%) and 6.2% (95%CI: 1.2-27.0%; two studies; I 2 = 69%) in schizophrenia and bipolar disorder, respectively. People with psychosis were more likely to have GAD65 antibodies than controls (odds ratio [OR], 2.24; 95%CI: 1.28-3.92%; P = 0.005; eight studies; I 2 = 0%). Among 21 participants with treatment-resistant psychosis, none had VGKC antibodies. The prevalence of VGKC antibodies is low in psychosis. Our preliminary meta-analysis suggests that GAD autoantibodies are more common in people with psychosis than in controls, although few studies accounted for the possibility of coexisting type 1 diabetes mellitus and the clinical significance of reported GAD titers remains unclear.
Antibodies to the voltage-gated potassium channel (VGKC) complex and glutamic acid decarboxylase (GAD) have been reported in some cases of psychosis. We conducted the first systematic review and meta-analysis to investigate their prevalence in people with psychosis and report a case series of VGKCcomplex antibodies in refractory psychosis. Only five studies presenting prevalence rates of VGKC seropositivity in psychosis were identified, in addition to our case series, with an overall prevalence of 1.5% (25/1720) compared to 0.7% in healthy controls (12/1753) . Meta-analysis established that the pooled prevalence of GAD65 autoantibodies was 5.8% (95% confidence interval [CI]: 2.0-15.6%; I 2 = 91%; nine studies) in psychotic disorders, with a prevalence of 4.6% (95%CI: 1.2-15.9%; nine studies; I 2 = 89%) and 6.2% (95%CI: 1.2-27.0%; two studies; I 2 = 69%) in schizophrenia and bipolar disorder, respectively. People with psychosis were more likely to have GAD65 antibodies than controls (odds ratio [OR], 2.24; 95%CI: 1.28-3.92%; P = 0.005; eight studies; I 2 = 0%). Among 21 participants with treatment-resistant psychosis, none had VGKC antibodies. The prevalence of VGKC antibodies is low in psychosis. Our preliminary meta-analysis suggests that GAD autoantibodies are more common in people with psychosis than in controls, although few studies accounted for the possibility of coexisting type 1 diabetes mellitus and the clinical significance of reported GAD titers remains unclear.
The paucity of studies reporting thresholds for defining GAD abnormality and rates of comorbid type 1 diabetes mellitus precludes interpretations regarding the influence of GAD antibodies on the development of psychotic disorders and may have led to an overestimate of the prevalence of GAD. Our case series fails to support the hypothesis that VGKC antibodies are linked to treatment resistance in psychosis, but the literature to date is remarkably sparse.
O VER RECENT YEARS, interest in a possible autoimmune etiology of psychosis has grown. 1, 2 It has long been known that people with schizophrenia and their families have a higher risk of autoimmune disease than the general population. [3] [4] [5] [6] Latterly, there has been interest in the subgroup of people with psychosis who have serum antibodies to neuronal antigens. 1, 7, 8 Most current interest focuses on antibodies to the N-methyl-D-aspartate receptor (NMDA-R), voltage-gated potassium channel (VGKC) complexes, and glutamic acid decarboxylase (GAD). [9] [10] [11] [12] A previous meta-analysis identified NMDA-R positivity in 7.98% (n = 115/1441) of schizophrenia spectrum psychosis. 8 Given this previous review of NMDA-R antibodies, we will not discuss these further in our study. Psychosis is a common feature of the encephalitis syndromes that are classically associated with these antibodies -often as an early feature before the development of other features of encephalitis, such as seizures, movement disorders, autonomic instability, and impaired consciousness. 13, 14 The importance of these antibodies is clear when psychosis presents in the context of encephalitis, but the challenge in psychiatry is to determine their relevance in clinically uncomplicated psychosis.
VGKC-complex antibodies
VGKC antibody-mediated limbic encephalitis was first described in 2001. 15 Most VGKC-complex antibodies are directed against neuronal cell surface antigens, where they bind to leucine-rich glioma inactivated-1 (LGI-1) or contactin-associated protein-2 (CASPR-2), which are cell surface proteins that form part of the VGKC-complex. 16 The targets of other VGKC-complex antibodies are unclear. In 2004, Vincent et al. reported a retrospective case series of 10 patients with VGKC antibody-mediated limbic encephalitis, several of whom had experienced psychiatric symptoms, such as hallucinations (n = 3), depression (n = 1), and anxiety and delusions (n = 1). 17 A later retrospective case series of 152 US patients who tested positive for serum VGKC antibodies reported neuropsychiatric symptoms in 44%, in particular anxiety and depression, with two patients initially given psychiatric diagnoses. 18 
GAD antibodies
GAD is the rate-limiting enzyme for the generation of gamma amino-butyric acid (GABA), the main inhibitory central nervous system neurotransmitter. 19 There are two subtypes of GAD. GAD65 is present in both pancreatic islet cells and neuronal tissue, while GAD67 is present mainly in neuronal tissue. 20 GAD autoantibodies are directed against intracellular synaptic antigens, and are found in several neurological conditions, such as Stiff person syndrome, limbic encephalitis, and epilepsy. 21 It is unclear whether the presence of GAD65 in these disorders is pathogenic or an epiphenomenon of another immune dysfunction.
GAD65 antibodies are also a marker for type 1 diabetes mellitus (DM) and latent autoimmune diabetes of adulthood. 22, 23 Patients with schizophrenia have an increased risk of type 1 DM. 3 
Aims of the current paper
There is no previous systematic review investigating the prevalence of VGKC seropositivity in psychosis. A systematic review of the prevalence of a variety of other antibodies in schizophrenia identified four studies assessing GAD antibodies.
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Given the aforementioned, we conducted a systematic review and meta-analysis to determine the prevalence of VGKC-complex and GAD antibodies in psychosis. The coprimary outcomes were the prevalence of study-defined VGKC and GAD positivity in psychosis. Secondary outcomes included the comparison of the coprimary outcomes in diagnostic subgroups (e.g., schizophrenia and bipolar disorder [BD]) with healthy controls. In addition, we aimed to describe the clinical characteristics of patients with VGKC-complex and GAD65 antibodypositive psychotic illness. Within the second stage of this paper, we conducted a retrospective case series to investigate VGKC-complex antibodies in patients with refractory psychosis.
METHODS
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standard. 24 
Inclusion and exclusion criteria
Included in this systematic review were studies that: (i) included subjects with a diagnosis of, or who were being treated for, a psychotic illness; (ii) analyzed serum or cerebrospinal fluid for the presence of VGKC or GAD antibodies; (iii) were comparative (contained a healthy control group) or non-comparative (without a control group) and were prevalence or observational; (iv) were published in peer-reviewed journals; (v) were written in English; and (vi) were published before June 2016.
The exclusion criteria were: (i) studies in which subjects were screened for antibodies as part of a medical work-up without an actual or suspected psychiatric diagnosis; and (ii) studies where individuals were diagnosed with an organic psychosis from the outset.
Information sources and searches
Two independent reviewers (R. G., J. L.) performed an electronic search using MEDLINE, PSYCHINFO, PUBMED, SCO-PUS, and GOOGLE SCHOLAR from database inception to June 2016. The following basic search terms were used, both alone and in combinations: 'psychosis,' 'psychotic' (and truncated terms 'psychos*,' 'psychot*'), 'schizophrenia,' 'schizoaffective,' and 'bipolar' were combined with 'gad,' 'glutamic acid decarboxylase,' 'glutamate decarboxylase,' 'diabetes,' 'VGKC,' 'voltagegated potassium channels,' 'CASPR,' and 'LGI1,' and 'antibodies,' 'antibody,' and 'antibod*. ' 'VGKC' alone was also searched to identify all records in PUBMED. The abstracts of the 2012, 2014, and 2016 Schizophrenia International Research Society and the 2009, 2011, 2013, and 2015 International Congress on Schizophrenia Research conferences were searched for abstracts containing 'antibod*' to identify any unpublished works. The titles of all articles retrieved were screened, and the abstracts of those considered potentially relevant were read. All articles considered relevant at this initial screening were retrieved and taken to full reading. A hand search of the references of retrieved articles was conducted to identify additional studies. When required, we contacted the primary/ corresponding authors of potential studies to: (i) confirm eligibility; and (ii) acquire the variables of interest if they were not available in the publication.
Study selection and exclusion
All applicable abstracts were obtained, and examined by two reviewers (R. G., J. L.). The two authors applied the eligibility criteria and a list of full text articles was developed through consensus.
Data extraction
Articles were critically reviewed by two authors (R. G., J. L.) and the following information extracted where available: clinical characteristics and outcomes; size of the cohort; diagnoses and any control groups; antibodies tested; threshold for antibody positivity; and numbers and proportions of patients with antibody positivity.
Meta-analysis
If data were sufficient, we anticipated conducting a random-effects analysis with COMPREHENSIVE META-ANAL-YSIS software (Version 3). First, we calculated the prevalence of GAD65 antibody positivity in each diagnostic subgroup (all psychotic disorders, schizophrenia, BD, and controls) together with 95% confidence intervals (CI). We then compared the prevalence of GAD65 antibodies in each cohort separately with the controls to determine the OR and 95%CI. Heterogeneity was assessed with the Cochran Q and I 2 statistics for each analysis. 25 Publication bias was assessed with a visual inspection of funnel plots and with the Begg-Mazumdar Kendall's tau 26 and Egger bias test.
27
Case series 
RESULTS

Systematic review
The results of the selection process are summarized in a flow diagram (Fig. 1 ).
VGKC studies
The results of the VGKC studies are summarized in Table 1 . 10, [29] [30] [31] [32] The literature search revealed five studies reporting on VGKC positivity in psychotic disorders. 10, [29] [30] [31] [32] Two of the studies measured VGKC antibodies using a radioimmunoprecipitation assay, 10, 29 while three used an immunofluorescence assay. [30] [31] [32] One of the studies assessed serum and cerebrospinal fluid for VGKC positivity. 32 Only one of the studies defined a cut-off for VGKC positivity with a VGKC level of >100 pM established as consistent with positivity. 29 Case series results VGKC in treatment-refractory psychosis Between August 2009 and February 2015, 203 patients with diagnoses of treatment-resistant psychosis were referred to our specialist inpatient service. Twenty-one patients (12 males) based on clinical suspicion were tested for VGKC-complex antibodies. The mean age was 38 years (SD = 17; range 19-78 years). Diagnoses were: schizophrenia (n = 14), schizoaffective disorder (n = 5), and psychotic depression (n = 2). The mean duration of illness was 12 years (SD = 10; range = 3-33 years). All patients tested negative for VGKC-complex antibodies.
The remaining five studies, 10, [29] [30] [31] [32] and our case series, described 1720 patients (1574 schizophrenia patients, 46 first-episode psychosis [FEP], 50 bipolar affective disorder, and 50 patients with unstated chronic psychotic disorders) and 1753 controls.
VGKC prevalence studies
The overall prevalence of VGKC-complex antibodies in cases was 1.5% (25/1720), with 0.7% (12/1753) in controls. 29, 30 One of the VGKCcomplex antibody-positive patients had a diagnosis of FEP, but presented with no distinguishing clinical features from other patients within the service. Table 2 presents the results of the GAD65 studies. The literature search revealed nine studies satisfying eligibility criteria. Eight of these were case-control studies 20, 29, 30, [33] [34] [35] [36] [37] and one was an observational study (with general population rates of GAD65 positivity used for comparison in Cohen et al. 38 ). All of the included studies assessed serum for GAD antibody positivity.
GAD65 antibody studies
GAD65 seropositivity in case-control and observational studies
The included studies involved 2019 psychosis patients and 2116 healthy controls. Fifty-seven patients were positive for GAD65 antibodies, giving a prevalence of 2.8% (57/2019). Eleven controls (20/2116; 0.95%) were positive for GAD65 antibodies. Rates of comorbidity with type 1 DM were not given in any of the studies. A definition of GAD positivity defined in units of GAD antibodies was used in only three of the case-control studies (GAD positivity defined as GAD65 antibodies >1.05 [20, 33] and positive with GAD levels >10 U/mL). Two other studies established cut-off values for GAD positivity at specified percentile of the control groups (97th percentile (35) and 98th percentile of the healthy control group GAD level 20 ). Of note, only serum titers higher than 1000 U/mL are generally considered related to neurological pathologies; none of the patients reported in these studies reached that threshold.
Diagnostic subgroupings
The only study in FEP patients reported a GAD65 antibody prevalence rate of 18.75%. These patients had no distinguishing features from other FEP patients within the service.
Case-control studies
One study found statistically significant differences in prevalence rates of GAD65 between cases and controls. Padmos et al. found that 11.3% of the BD group had positivity for serum antibodies to GAD65 compared with only 2.6% of the healthy control group (P = 0.002). 33 Patients with GAD65 positivity had more active forms of the illness (either mania/ hypomania or depression) compared with the GAD65-negative patients. GAD65 levels were not found to significantly correlate with duration of illness or treatment, symptom severity, or rapid cycling. Seven case-control studies did not find Seven of the case-control studies assessed antibody levels in patient and control groups and two found statistically significant differences. Padmos et al. identified a mean GAD65A index that was significantly higher in bipolar patients compared with control subjects (P = 0.038). In the same study there was no significant difference in the mean GAD65 index between schizophrenia patients and controls. 33 Yarlagadda et al. found that patients with chronic psychosis and TD had significantly higher antibody levels compared to chronic psychosis patients without TD (P = 0.044), with 38.5% of the TD group (5/13) being positive for GAD65 antibodies, and no antibodies found in patients without TD (0/7). 
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GAD65 and GAD67
Three studies tested for both GAD65 and 67 antibody positivity in patient and control groups, 20, 30, 33 with significantly increased rates of GAD65, but not GAD67, found in BD cases in two of the studies.
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META-ANALYSIS RESULTS
There was insufficient data to pool the prevalence of VGKC-complex antibodies.
GAD65 antibodies
It was possible to pool data from nine studies to establish that the pooled prevalence of GAD65 antibodies among people with psychosis was 5.8% (95%CI, 2.0-15.6%; I 2 = 91%; nine studies) with no evidence of publication bias (Begg = −0.14, P = 0.6; Egger = −0.43, P = 0.84; Fig. 2) ; the prevalence of GAD65 antibodies was 4.6% (95%CI, 1.2-15.9%; nine studies; I 2 = 89%; Begg = 0.00, P = 1.0; Egger = 1.50, P = 0.54) and 6.2% (95%CI, 1.2-27.0%; two studies; I 2 = 69%) in schizophrenia and BD participants, respectively. The prevalence of GAD65 antibodies was 2.7% (95%CI, 1.0-7.0%; eight studies; I 2 = 73%) among healthy controls.
Risk of GAD65 antibodies in psychosis versus controls
A comparative meta-analysis established that people with psychosis were more than two times more likely to have GAD65 antibodies (OR, 2.24; 95%CI, 1.28-2.92%; P = 0.005; eight studies; I 2 = 0%) than controls (Fig. 3) . No significant difference was observed in schizophrenia participants versus controls (OR, 1.49; 95%CI, 0.76-2.92%; P = 0.24; six studies; I 2 = 0%). An increased OR was observed in BD participants versus controls but caution should be noted as only two studies were pooled in the analysis (OR, 4.41; 95%CI, 1.85-10.5; P < 0.001; I 2 = 0%).
DISCUSSION
To our knowledge, this is the first systematic, quantitative review of studies on VGKC and GAD antibodies in schizophrenia and psychotic spectrum disorders. There are several findings of note. We have carried out the largest review of GAD antibodies in psychosis. Our meta-analysis establishes that the prevalence of GAD antibodies among people with psychosis was 5.8% (95%CI, 2.0-15.6%), whilst 4.6% (95%CI, 1.2-15.9%) and 6.2% (95% CI, 1.2-27.0%) of people with schizophrenia and BD tested positive, respectively. Moreover, our comparative meta-analysis suggests that people with psychosis are at a more than twofold risk of having GAD autoantibodies compared to the general population (OR, 2.24; 95%CI, 1.28-2.92%; P = 0.005). Whilst we generally found low or moderate levels of heterogeneity and no publication bias, the sample sizes are relatively small and some methodological differences exist. We identified a pooled prevalence rate of 5.8% for GAD65 in psychotic disorders, with a rate of 2.7% in controls. The case-control studies of GAD65 in psychotic disorders were marked by methodological heterogeneity, which makes the interpretation of results difficult. Except for Dahm et al. 30 and Padmos et al.
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Study name Statistics for each study Event rate
Lower limit
Upper limit Event rate and 95%CI
Yarlagadda et al. 35 Yarlagadda et al. 36 Padmos et al. 33 Yarlagadda et al. 20 Lennox et al. 37 Cohen et al. 38 Gaughran et al. 34 Çoban et al. 29 Dahm et al. © 2017 The Authors Psychiatry and Clinical Neurosciences © 2017 Japanese Society of Psychiatry and Neurology studies had small sample sizes, with contrasting methodologies used to measure and detect GAD antibodies. Three studies 29, 35, 36 used the enzymelinked immunosorbent assay method, with GAD levels calculated using absorbance values, rather than by antibody titers as in the 2011 Yarlagadda group study. 20 The other studies used radioimmunoassays to measure GAD antibodies.
It is possible that GAD65 antibodies may directly affect the brain. Abnormalities in GABA have been implicated in schizophrenia 39, 40 and GAD is the major rate-limiting enzyme in GABA production. 41 One significant limitation in the available data is the lack of information on comorbid type 1 DM, which may have explained some of the findings. Nevertheless, the excess of type 1 DM in schizophrenia is of a smaller magnitude (3.1%) 4 than the excess of GAD65 antibodies reported here, and type 1 DM is unlikely to account for all of these findings. Further, the paucity of studies defining the threshold for abnormal GAD levels limits interpretation of the influence of GAD antibodies on the development of psychotic disorders, particularly since GAD antibody levels of >1000 IU/L are considered to be indicative of a need for immunotherapy in neurological disorders. 42 We found a low prevalence of VGKC positivity in psychotic disorders, in the context of a paucity of prevalence studies. The available data (five studies) identified 25 patients with VGKC antibodies. 10, 30, 32 This low prevalence is consistent with the findings in our case series in treatment-resistant psychosis where no VGKC antibody-positive patients were identified.
Contrary to expectations, there was a low prevalence of VGKC positivity, which may be reflective of the currently attainable sample size due to a low number of studies. Only two studies have assessed VGKC positivity in cases and controls, 29, 30 thus limiting our ability to draw firm conclusions, though the majority of cases sampled were drawn from these two studies. In extracting data in relation to VGKC-complex antibodies, we compiled an overall prevalence rate, including studies assessing for antibodies against any component of the VGKC complex, including LGI1 and CASPR antibodies. This method of data extraction may have led to an underestimation of those antibodies that are more closely related to encephalitis, namely LGI1 and CASPR. Further, given that VGKC-complex antibody positivity tends to occur in the acute encephalitic stage, the lack of data on the stage of illness at which cases were tested for VGKC-complex antibodies is a limitation. Thus, we cannot exclude the possibility that the prevalence of VGKC complex antibody positivity would be higher in more acute stages of illness, and that negative results in later stages, or more chronic stages, do not outrule an autoimmune etiology.
Clinical characteristics of VGKC-positive cases
There were no prototypical clinical characteristics reported for these VGCK-positive patients identified in our review. In Endres et al. 32 two of the cases presented with neurological features, one with fluctuating levels of consciousness, and another with seizures, aphasia, and stupor. 32 One patient was unfortunately lost to follow-up, although the lack of distinguishing factors makes that case clinically important. 10 When VGKC antibodies are found in patients with limbic encephalitis with an initial presentation of psychotic illness, these cases do not indicate a characteristic phenotypic presentation of VGKC antibody-related Dahm et al. 30 Yarlagadda et al. 36 Yarlagadda et al. 35 Padmos et al. 33 Yarlagadda et al. 20 Lennox et al. 37 Gaughran et al. 34 Çoban et al. limbic encephalitis, although neurological signs and seizures should raise suspicion of this. Data from case reports of VGKC-complex limbic encephalitis with an initial presentation of psychosis (n = 5) indicate a broad clinical heterogeneity, including seizure-like episodes (n = 4), disordered speech (n = 3), delusions (n = 3), behavior change (n = 2), aggression (n = 2), depressive symptoms (n = 2), auditory and visual hallucinations (n = 2), self-harm (n = 1), mutism (n = 1), and hyponatremia (n = 3). [43] [44] [45] [46] [47] More studies with larger cohorts are needed in order to give a more robust estimate of the prevalence of VGKC antibody positivity in psychosis. This may identify subgroups of patients with higher rates of VGKC antibodies, and determine when VGKC antibody testing is indicated.
Clinical implications of GAD positivity
This review identified one case report of limbic encephalitis presenting with psychosis in the presence of GAD autoantibodies. 48 A female patient was diagnosed with treatment-resistant schizophrenia aged 17 years. Subtle abnormal features, such as intermittent semirhythmic diffuse theta slowing on electroencephalogram monitoring, without epileptiform abnormalities, and episodes of impaired responsiveness, were not associated with electroencephalogram changes and prompted a frontal lobe biopsy that showed immunological activity. Serum GAD65 antibody levels were 112 IU/mL (normal range 0-5). Treatment with immunosuppressive therapies resulted in some improvement, but not the excellent recovery seen in many of the VGKC-complex antibody cases. It is possible that the pathogenesis in this case was not GAD autoantibody-mediated and reflected a comorbid condition. Furthermore, the symptom profile in this case was more characteristic of schizophrenia, with no seizure activity, neurological signs, or hyponatremia identified.
Implications for future research
Further studies are needed to determine whether GAD65 antibodies are related to the pathogenesis of psychotic disorders, and if so with which particular clinical features. Future studies should also control for potential confounding factors, such as age, ethnicity, body mass index, antipsychotic medication use, stage of illness, and, importantly, a diagnosis of type 1 DM.
It is possible that autoimmune-mediated brain changes may occur early in life, with antibody levels becoming reduced or undetectable following a long duration of psychosis.
Case series of VGKC-complex antibody positivity in treatment-resistant schizophrenia Our case series found a zero prevalence rate for VGKC antibodies in patients with refractory psychosis. The case series was small, with a low frequency of testing. However, the clinicians who selected those tested had an interest in the autoimmune causes of psychosis, which is likely to have introduced an overestimate rather than an underestimate. It is possible that antibody titers could be affected by treatment, as antipsychotic medication can have immunomodulatory effects, 49 and we are unable to exclude the possibility that patients are more likely to test positive for autoantibodies early in the course of their illness or when drug-naive. Based on this case series, routine testing for VGKC antibodies cannot be recommended in refractory psychosis.
Conclusions
The potential for VGKC and GAD antibodies to cause psychosis is a fairly novel proposal, and relatively few studies exist. This review has identified five studies on VGKC antibodies in psychosis and, including our case series, the prevalence stands at 1.5% (25/1720). There remain unsolved issues and more studies are needed on larger patient cohorts to give a more accurate picture of prevalence and the role(s) of these antibodies.
This review identified an overall pooled prevalence rate of 5.8% for GAD65 antibody-positivity in psychosis. More studies are needed to gain a more accurate picture of GAD65 antibody prevalence in psychosis and to determine whether these antibodies are clinically relevant to the disease process.
Key learning points
• This was the first meta-analysis on the relations of VGKC and GAD antibodies with psychotic disorders.
• There are few studies on VGKC antibody positivity in psychosis, but the available evidence indicates a low prevalence (1.5%).
• Our results do not support the hypothesis that a significant subpopulation of those with psychotic disorders are patients with misdiagnosed VGKCantibody positive autoimmune limbic encephalitis.
• The raw, unadjusted prevalence rates of GAD positivity were 2.8% in psychosis and 0.95% in controls. Meta-analysis identified a pooled prevalence for GAD antibodies of 5.8% in psychosis compared to 2.7% in healthy controls.
• More patients were identified as having GAD antibodies, but there are still few studies overall and the clinical significance of the titers reported is unclear. A paucity of studies reporting on concurrent type 1 DM indicates that the identified prevalence rate of GAD antibodies may be somewhat accounted for by concurrent type 1 DM.
• Our review demonstrates that patients with psychosis have an increased likelihood of GAD antibody positivity; however, the extent to which this finding contributes to the etiology of psychotic disorders remains uncertain.
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